Key result
Shugan Quzhi Capsules target PPAR and AMPK pathways to potentially treat NAFLD, hyperlipidemia, and obesity.
Why the study?
To explore the mechanism effects of the traditional Chinese medicine concept of The Same Treatment for Different metabolic Diseases.
What are the mechanisms of action of Shugan Quzhi Capsules in treating obesity, hyperlipidemia, and NAFLD?
What are the mechanisms of action of Shugan Quzhi Capsules in treating obesity, hyperlipidemia, and NAFLD?
Network pharmacology and molecular docking suggest that Shugan Quzhi Capsules may treat metabolic diseases through multiple targets and pathways, particularly leptin, apolipoprotein B, and PPAR signaling.
No clinical practice change indicated for metabolic disease; hypothesis-generating for multi-target herbal effects in NAFLD and obesity.
Purpose: We explored the mechanism effects of “The Same Treatment for Different metabolic Diseases” concept in traditional Chinese medicine (TCM).Methods: Network pharmacology, molecular docking technology and KATZ score were employed to predict the targets and signaling pathways affected by Shugan Quzhi Capsules (SGQZ), which are used to treat obesity, hyperlipidemia, and non-alcoholic fatty liver disease.Results: A total of 492 active ingredients in SGQZ were found to act on 666 potential targets. They were involved in GO biological processes related to lipid metabolism, oxidative stress, anti-inflammatory effects, and calcium ion channel effects; the three most significantly enriched KEGG pathways were endocrine resistance, advanced glycation end-product (AGE)/receptor for AGEs signaling pathway in diabetic complications, and peroxisome proliferator-activated receptor (PPAR) signaling. The correlation between SGQZ and each metabolic disease was ranked as NAFLD>hyperlipidemia>obesity.Conclusions: Our results clarify the mechanisms of action of SGQZ on three conditions, demonstrating the utility of “The Same Treatment for metabolic Different Diseases” from both the target and pathway perspectives. Among them, leptin, apolipoprotein B, and PPARG and PPAR-/AMP-activated protein kinase-related signal pathways are the key targets and pathways for SGQZ. In TCM terminology, the spleen and liver meridians are the key routes by which quercetin and apigenin in SGQZ exert their effects.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2021) studied Obesity, hyperlipidemia, and non-alcoholic fatty liver disease. Shugan Quzhi Capsules (SGQZ) was evaluated on Potential targets and signaling pathways. Shugan Quzhi Capsules contain 492 active ingredients that act on 666 potential targets, primarily affecting PPAR and AMPK pathways to treat NAFLD, hyperlipidemia, and obesity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: